Doc 0000151761

This page features a stylized graphic of a vault door on the left side, with a dark background. To the right of the vault, prominent white text proclaims "THE BLACK VAULT" in a distinctive font. Below this title, an informational paragraph in smaller white text explains that the document was obtained from "The Black Vault," an online database of declassified government documents, specifically referencing the "MKULTRA/Mind Control Collection." The text also provides a URL for accessing the collection online: "http://mkultra.theblackvault.com." There are no photographs, handwritten annotations, stamps, forms, diagrams, tables, redactions, or visual evidence of experimental procedures. 13 May 1959 ELYM~CI.AVINE (43-Y) • . · Elymoclavine (V~A-22) is a material isolated frqm a cultured saprophytic fungus by the Research Laboratories of Ta!<eda Pharmaceutical Industr:ies in 8apan. It is related to agro- clavine (V-A-18) and t' o dlhydro~groclavine, both of which have sedative and hypno~ic effects in man,:although they are primarily ex~itant in animals. All these drugs are related to the ergot group. ·In elymoclavine ~he acid amide group of LSD has been replaced with a hydrogen and a c~2oH group • . Accord.lng to Yui and Takeo (1) agroclavlne and elymoclavine of cause a syndrome ncentral sympathetic excitationn in mice, rabbits, cats and dogs manifested by mydriasis, tachypnea, "· con~lsions, hyperactivity, etc; whereas dihydroagroclavine, ' dihydroergoltryptfne, etc., cause sedation. Elymoclav!ne a11.d agroclavine had analeptic effects in reserpine sedated mice. Because of discrepancy in the effects of agroclavine (in animals, excitation and in man, sedation) a preliminary study of elymoclavine was thought to be of interest. The study was designed to determine the effective dose range in man, and to determine if LSD-llke (psychosomimetic) effects were induced. '! Page 2 METHODS Subjects. Nontolerant former opiate addicts who were .· serving sentences for violating the Federal narcotic laws " volunteered for these experiments. All were healthy males between 21 and 40 years. of ag_~ who presented no evidence of . '..- any of the major psychoses on mental status examinations. All had experienced the atfects of in previous experiments. LSD-2~. General Conditions. The experiments were conducted in a / special ward. Patients entered this ward on the night before experiments were conducted, and were observed hourly by specially_tralned attendants. B' etween observati9ns the patients were free to remain in their own rooms, to sleep or to socialize with other pati-ents in a common day room. ~rugs. Elymoclavine was given orally in solution at 8 a.m. . . The taste was masked with cherry ~yrup. In preliminary experiments·, the dose of elymoclavine was .. 7.5 cautiously elevated from 1 meg/kg to meg/kg. No psycho- somimetic effects were observed, and with the larger doses patients began to report headaches and ·drowsiness. Accordingly e) - J Pag~ more formal experiments were carried out in which 12 patients received on two separate occasions 10 and 15 meg/kg of V-A-22. In addition, 5 patients ·received 20 meg/kg· and 4 received 25 meg/kg. Observations. The fo.llowing observations were made at· hourly intervals twice before~and eight The page contains a typewritten document with handwritten annotations. In the upper right quadrant, there's a circular doodle with the number "162" written inside. A handwritten number "13-236" appears in the bottom right corner. The text discusses the properties and effects of Elymoclavine and related compounds, mentioning its isolation from a fungus and its potential as a psychoactive substance. There are no images of people, locations, equipment, or facilities, nor are there any official stamps, forms, diagrams, or tables visible on this page. Accordingly e) - J Pag~ more formal experiments were carried out in which 12 patients received on two separate occasions 10 and 15 meg/kg of V-A-22. In addition, 5 patients ·received 20 meg/kg· and 4 received 25 meg/kg. Observations. The fo.llowing observations were made at· hourly intervals twice before~and eight times after adminis- '..- tration of V-A-22: pu.pillary size, sys·tolic blood pressure, . . . and threshold for e}iciting the kneej~rk. In addition patients completed a questionnaire hourly, with the help of an aide, and " short mental stat~s examinations were made at appropriate intervals. The methods of making the observations and analyzing -- the data were described by Isbell et al (2,3). For comparative purposes, data on 9 other subjects who received a placebo and 1.0 meg/kg of LSD in other experiments are included. RESULTS The combined data are presented in Table 1 which shows that, as compared with LSD, elymoclavine had relatively minor effects on pupillary diameter, threshold for kneejerk, and blood 25 pressure {except at·the meg/kg level). The table also shows 25 the lack of any psychosomimetic effect, even with meg/kg. Positive responses on the questionnaire after elymoclavine were usually to such items as: "I feel sleepy," "I am nauseated," etc. --- 4 Page V-A-22 did, however., induce symptoms differing from thos~ of LSD. The mas~ commonly reported symptoms were sleepiness and relaxation .(Table 2). DISCUSSION Like agroclavine and Lilfy 23194, elymoclavine had sedative effect, rather than ps"ychosomi m~t i c e_ffec.ts in man. Whether · such sedation could- be exploite.d therapeutically remains to be determined. / In further work, the sleep-inducing properties of elymoclavine should be compared with those of a barbiturate. !3-2'3 --- Page 5 REFERENCES .· 1. YUI, T. and TAKEO, Y.: Neuropharmacologica} studies on a new series of ergot alkaloi'ds. Elymoclavine as. a potent ., analeptic on reserpine sedatfon. Japanese J. Pharmacol., 1= I 1.57-161 (March) 19.58. ·. · 2. ISBELL, H./ BELLEVILLE;. R. E., FRASER, H. F., WIKLER, A., and LOGAN,. <Y. R.: Studies on lysergic acid diethylamide. I. Effects in former morphine addicts and development of toleran=e during chronic intoxication. A.M.A. Arch. Neurol. .12! b Psychiat., 468-478 (Nov.) 19.56. 3. ISBELL, H., C. R., and E. J.: Studies LOG.~~, MIN~~~ on lysergic acid diethylamide (LSD-2.5). III. Attempts to attenuate the L·SD-reaction in man by pretreatment with neuro humoral blocking agents. A.M.A. Arch. Neurol. & Psychiat., -81: 20-27 (Jan.) 19.59 •. -~ Arch. Neurol. .12! b Psychiat., 468-478 (Nov.) 19.56. 3. ISBELL, H., C. R., and E. J.: Studies LOG.~~, MIN~~~ on lysergic acid diethylamide (LSD-2.5). III. Attempts to attenuate the L·SD-reaction in man by pretreatment with neuro humoral blocking agents. A.M.A. Arch. Neurol. & Psychiat., -81: 20-27 (Jan.) 19.59 •. -~ ' .j ,',I f't)' 1. ry ~- ~ Table 1. Comparison of the Effects of Elymoclavine (V-A-22) with those of LSD-25. /. . I DRUG AND DOSE ~mcgLkg~ 1 . 1 r.m/\"uRE Placebo! ELYMOCLAVINE --. 2s---- LSD-25 1.0 10 15 20 Pupillary Size 0.2 :!: l.l~ + 10.2 '± . 1. 2 - o.l~ ± 1. 3 - 1.2 ± 1. 3 + 3.0 ± 2.2 - 1.9 ± 2.5 Blood Pressure +15.6 ± 13.5. 61~. 8 ± 10.9 +25 t 11 +43 ± ~~- +21~ :t 12 ( .+91+.5 ± 8. 7 .. . . Threshold for .. \ Jmeejerk +20. 7 ± 11 ~5o. 9 ± 31 - 7.6 ± 1.~. - 8 ± 1.5 -16.7 ± 9 +10 ± 9 T' Tt::·t.a1 positive . n:sponses on Ouestlonnalre 0.1 :!: 0.) 57" .. ± 2).2 5 ± 1. 3 7 .J ± 1.9 5.2 ± ).2 6.5 ± 3.9 \ Clinical Grade 0:!: 0 2.2 ± \ 0.4 0 ± 0 0 :!: 0 0 ± 0 0 ± 0 • I .• ""'"" ....,ssr=r:tr I -=a:~- #I I ., • CCCI " II* I MC'- . ... : ):! =::w•,.._=za ' 1. Figures are means ± sta~dard errors of observations on 9 subjects in the C' case of placebo and 1 meg/kg of LSD; 12 subjects in case of 10 and 15 meg/kg of V-A-22; 5 subjects in case of 20 mcg/ltg of V-A-22; and 4 subjects in case . 25 of meg/kg of V-A-22. /'"""· \ . 7 Page Table 2.· Incidence. of Certain Symptoms after Elymoclavine. . DOSE (meg/kg) •. J. . Q 15 20 25 Number of Subiects SYrv!PTOMS 12 12 5 1.L Sleepiness 9 9 3 2 / Relaxed 7 8 3 2 Headache 2 4 2 0 Nausea 3 4 2 2 Dizziness 0 0 1 0 Feel ndifferent" 7 8 2 2 The document page contains typed text and handwritten annotations. The text details the methodology of an experiment involving Nontolerant former opiate addicts, including aspects like subject selection, experimental conditions, and drug administration. Handwritten marginalia is present in the bottom right corner, marked as "B-233". There is no photographic or diagrammatic content, nor are there any official stamps or redactions visible on this page. The visual elements are limited to the typed report text and the handwritten notation. The document appears to be a page from a research report, indicated by the heading "Page 3" and the section title "RESULTS." The text describes experimental procedures, observations, and data analysis related to drug administration and patient responses. There are no photographs, diagrams, or forms visible. However, there is a handwritten annotation in the bottom right corner, "B-23-", which may be a page number, document identifier, or some form of internal tracking mark. The overall impression is of a densely typed page of scientific text, with only the handwritten annotation providing a visual deviation from the printed content. This page contains text from a declassified document, likely a research report, with a heading "DISCUSSION." There are no images, stamps, forms, diagrams, or tables. The only handwritten annotation is "B-23" in the lower right corner. There are no visible redactions or evidence of experimental procedures. The page contains a list of references, likely from a scientific or research document. There are no photographs, diagrams, tables, or forms visible. There is handwritten marginalia in the bottom right corner, which reads "B-232". There are also a few minor handwritten marks and smudges throughout the page, and a bold line near the top right corner that could be a page marker. The rest of the page is filled with typed text. The page contains a table labeled "Table 1" that presents data comparing the effects of Elymoclavine (V-A-22) with LSD-25. The table includes columns for different drugs and doses, and rows for various physiological and psychological measures such as Pupillary Size, Blood Pressure, Threshold for Knee Jerk, Total positive responses on Questionnaire, and Clinical Grade. There is a handwritten annotation in the top right corner of the page that reads "B-23," and some marginal marks. The bottom of the page contains numbered text, likely footnotes or explanations of the table's data, indicating the number of subjects involved in the study for each condition. The overall appearance is that of a scanned document from a scientific or research report. The page displays a table titled "Table 2. Incidence of Certain Symptoms after Elymoclavine." This table presents data on various symptoms, including sleepiness, relaxed, headache, nausea, dizziness, and feeling "different," across different dosages of Elymoclavine (10, 15, 20, and 25 mcg/kg). Below the dosage information, the number of subjects for each dosage is indicated as 12, 12, 5, and 4 respectively. The table is primarily composed of numerical data, with some handwritten annotations at the bottom right corner that appear to be a document identifier, "B-230." The page is otherwise blank, with no images, stamps, or diagrams present.